Ocugen’s COVID-19 vaccine development partner, Bharat Biotech, shares provisional results of COVAXIN phase 3, demonstrates 81% Nasdaq efficacy: OCGN
The European Commission grants the designation of Ocugen orphan drug products for candidates for gene therapy products, OCU400, for the treatment of retinitis pigmentosa and congenital amberosis of Leber
